PURPOSE: We evaluated clinical outcomes in the subset of patients who underwent radiotherapy (RT) due to progressive pilocytic astrocytoma within the Multicenter Treatment Study for Children and Adolescents with a Low Grade Glioma HIT-LGG 1996. PATIENTS AND METHODS: Eligibility criteria were fulfilled by 117 patients. Most tumors (65 %) were located in the supratentorial midline, followed by the posterior fossa (26.5 %) and the cerebral hemispheres (8.5 %). Median age at the start of RT was 9.2 years (range 0.7-17.4 years). In 75 cases, external fractionated radiotherapy (EFRT) was administered either as first-line nonsurgical treatment (n = 58) or after progression following primary chemotherapy (n = 17). The median normalized total dose was 54 Gy. Stereotactic brachytherapy (SBT) was used in 42 selected cases. RESULTS: During a median follow-up period of 8.4 years, 4 patients (3.4 %) died and 33 (27.4 %) experienced disease progression. The 10-year overall (OS) and progression-free survival (PFS) rates were 97 and 70 %, respectively. No impact of the RT technique applied (EFRT versus SBT) on progression was observed. The 5-year PFS was 76 ± 5 % after EFRT and 65 ± 8 % after SBT. Disease progression after EFRT was not influenced by gender, neurofibromatosis type 1 (NF1) status, tumor location (hemispheres versus supratentorial midline versus posterior fossa), age or prior chemotherapy. Normalized total EFRT doses of more than 50.4 Gy did not improve PFS rates. CONCLUSION: EFRT plays an integral role in the treatment of pediatric pilocytic astrocytoma and is characterized by excellent tumor control. A reduction of the normalized total dose from 54 to 50.4 Gy appears to be feasible without jeopardizing tumor control. SBT is an effective treatment alternative.
PURPOSE: We evaluated clinical outcomes in the subset of patients who underwent radiotherapy (RT) due to progressive pilocytic astrocytoma within the Multicenter Treatment Study for Children and Adolescents with a Low Grade Glioma HIT-LGG 1996. PATIENTS AND METHODS: Eligibility criteria were fulfilled by 117 patients. Most tumors (65 %) were located in the supratentorial midline, followed by the posterior fossa (26.5 %) and the cerebral hemispheres (8.5 %). Median age at the start of RT was 9.2 years (range 0.7-17.4 years). In 75 cases, external fractionated radiotherapy (EFRT) was administered either as first-line nonsurgical treatment (n = 58) or after progression following primary chemotherapy (n = 17). The median normalized total dose was 54 Gy. Stereotactic brachytherapy (SBT) was used in 42 selected cases. RESULTS: During a median follow-up period of 8.4 years, 4 patients (3.4 %) died and 33 (27.4 %) experienced disease progression. The 10-year overall (OS) and progression-free survival (PFS) rates were 97 and 70 %, respectively. No impact of the RT technique applied (EFRT versus SBT) on progression was observed. The 5-year PFS was 76 ± 5 % after EFRT and 65 ± 8 % after SBT. Disease progression after EFRT was not influenced by gender, neurofibromatosis type 1 (NF1) status, tumor location (hemispheres versus supratentorial midline versus posterior fossa), age or prior chemotherapy. Normalized total EFRT doses of more than 50.4 Gy did not improve PFS rates. CONCLUSION:EFRT plays an integral role in the treatment of pediatric pilocytic astrocytoma and is characterized by excellent tumor control. A reduction of the normalized total dose from 54 to 50.4 Gy appears to be feasible without jeopardizing tumor control. SBT is an effective treatment alternative.
Authors: G G Grabenbauer; U Schuchardt; M Buchfelder; C M Rödel; G Gusek; M Marx; H G Doerr; R Fahlbusch; W J Huk; D Wenzel; R Sauer Journal: Radiother Oncol Date: 2000-03 Impact factor: 6.280
Authors: Elizabeth A Kidd; David B Mansur; Jeffrey R Leonard; Jeff M Michalski; Joseph R Simpson; Arie Perry Journal: J Neurooncol Date: 2005-08-11 Impact factor: 4.130
Authors: Tore Stokland; Jo-Fen Liu; James W Ironside; David W Ellison; Roger Taylor; Kathryn J Robinson; Susan V Picton; David A Walker Journal: Neuro Oncol Date: 2010-09-22 Impact factor: 12.300
Authors: Katrin Scheinemann; Ute Bartels; Elena Tsangaris; Cynthia Hawkins; Annie Huang; Peter Dirks; Iris Fried; Eric Bouffet; Uri Tabori Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett Journal: J Neurosurg Date: 1997-05 Impact factor: 5.115
Authors: Rolf-Dieter Kortmann; Beate Timmermann; Roger E Taylor; Giovanni Scarzello; Ludwig Plasswilm; Frank Paulsen; Branislav Jeremic; Astrid K Gnekow; Karin Dieckmann; Sylvia Kay; Michael Bamberg Journal: Strahlenther Onkol Date: 2003-08 Impact factor: 3.621
Authors: C Pfitzer; C-M Chen; T Wessel; T Keil; A Sörgel; T Langer; D Steinmann; A Borgmann-Staudt Journal: J Cancer Res Clin Oncol Date: 2014-05-20 Impact factor: 4.553
Authors: Matthew W Parsons; Nicholas S Whipple; Matthew M Poppe; Joe S Mendez; Donald M Cannon; Lindsay M Burt Journal: J Neurooncol Date: 2020-10-31 Impact factor: 4.130
Authors: Minh-Phuong Huynh-Le; Amanda J Walker; Peter C Burger; George I Jallo; Kenneth J Cohen; Moody D Wharam; Stephanie A Terezakis Journal: Childs Nerv Syst Date: 2016-05-14 Impact factor: 1.475
Authors: Omer Sager; Ferrat Dincoglan; Selcuk Demiral; Bora Uysal; Hakan Gamsiz; Esra Gumustepe; Fatih Ozcan; Onurhan Colak; Ahmet Tarik Gursoy; Cemal Ugur Dursun; Ahmet Oguz Tugcu; Galip Dogukan Dogru; Rukiyye Arslan; Yelda Elcim; Esin Gundem; Bahar Dirican; Murat Beyzadeoglu Journal: World J Exp Med Date: 2022-05-20
Authors: Amar Gajjar; Daniel C Bowers; Matthias A Karajannis; Sarah Leary; Hendrik Witt; Nicholas G Gottardo Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544